Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Deb Mills

Dr Deb Mills

Travel Medicine Update for General Practice

Dr Katherine Spira

Dr Katherine Spira

Choosing the Right Migraine Preventative

Dr Jay Ramanathan, A/Prof David Sullivan, facilitated by A/Prof Ralph Audehm

Dr Jay Ramanathan, A/Prof David Sullivan, facilitated by A/Prof Ralph Audehm

Expert Panel – Atherosclerosis and Blood Lipid Management

A/Prof Daryl Efron

A/Prof Daryl Efron

Autism – When & Who to Refer

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022